194 related articles for article (PubMed ID: 20460482)
1. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
Zhang W; Choi J; Zeng W; Rogers SA; Alyea EP; Rheinwald JG; Canning CM; Brusic V; Sasada T; Reinherz EL; Ritz J; Soiffer RJ; Wu CJ
Clin Cancer Res; 2010 May; 16(10):2729-39. PubMed ID: 20460482
[TBL] [Abstract][Full Text] [Related]
2. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
3. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
Yang XF; Wu CJ; McLaughlin S; Chillemi A; Wang KS; Canning C; Alyea EP; Kantoff P; Soiffer RJ; Dranoff G; Ritz J
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7492-7. PubMed ID: 11416219
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
[TBL] [Abstract][Full Text] [Related]
5. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J
J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585
[TBL] [Abstract][Full Text] [Related]
6. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
7. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
8. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.
Wu CJ; Yang XF; McLaughlin S; Neuberg D; Canning C; Stein B; Alyea EP; Soiffer RJ; Dranoff G; Ritz J
J Clin Invest; 2000 Sep; 106(5):705-14. PubMed ID: 10974024
[TBL] [Abstract][Full Text] [Related]
9. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
Biernacki MA; Marina O; Zhang W; Liu F; Bruns I; Cai A; Neuberg D; Canning CM; Alyea EP; Soiffer RJ; Brusic V; Ritz J; Wu CJ
Cancer Res; 2010 Feb; 70(3):906-15. PubMed ID: 20103624
[TBL] [Abstract][Full Text] [Related]
10. Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.
Kremer AN; van der Griendt JC; van der Meijden ED; Honders MW; Ayoglu B; Schwenk JM; Nilsson P; Falkenburg JH; Griffioen M
Haematologica; 2014 Feb; 99(2):365-9. PubMed ID: 24097630
[TBL] [Abstract][Full Text] [Related]
11. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
12. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
[TBL] [Abstract][Full Text] [Related]
13. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH
Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499
[TBL] [Abstract][Full Text] [Related]
14. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
Suemori K; Fujiwara H; Ochi T; Azuma T; Yamanouchi J; Narumi H; Yakushijin Y; Hato T; Hasegawa H; Yasukawa M
Cancer Sci; 2008 Jul; 99(7):1414-9. PubMed ID: 18422754
[TBL] [Abstract][Full Text] [Related]
15. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.
Castro FA; Palma PV; Morais FR; Voltarelli JC
Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574
[TBL] [Abstract][Full Text] [Related]
16. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
Dazzi F; Szydlo RM; Goldman JM
Exp Hematol; 1999 Oct; 27(10):1477-86. PubMed ID: 10517488
[TBL] [Abstract][Full Text] [Related]
17. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
[TBL] [Abstract][Full Text] [Related]
18. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
20. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
